GT200100220A - Nuevos heteroaromatos. - Google Patents

Nuevos heteroaromatos.

Info

Publication number
GT200100220A
GT200100220A GT200100220A GT200100220A GT200100220A GT 200100220 A GT200100220 A GT 200100220A GT 200100220 A GT200100220 A GT 200100220A GT 200100220 A GT200100220 A GT 200100220A GT 200100220 A GT200100220 A GT 200100220A
Authority
GT
Guatemala
Prior art keywords
heteroaromatos
new
pharmaceutically acceptable
compounds
diseases
Prior art date
Application number
GT200100220A
Other languages
English (en)
Inventor
Johannes Aebi
Jean Ackermann
Henrietta Dehmlow
Hans-Peter Maerki
Olivier Morand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100220A publication Critical patent/GT200100220A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA I, DONDE U, A1, A2, A3, A9, V, X, Y, Z, Q, M Y N SE DESCRIBEN EN EL EXPEDIENTE, ADEMAS SE REFIERE A SALES FARMACEUTICAMENTE ACEPTABLES Y/O ESTERES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMO. LOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO Y/O PREVENCION DE ENFERMEDADES QUE ESTAN ASOCIADAS CON 2,3OXIDOESCUALENOLANOSTEROL CICLASA TALES COMO HIPERCOLESTEROLEMIA, HIPERLIPEMIA, ARTERIOSCLEROSIS, ENFERMEDADES VASCULARES, MICOSIS, CALCULOS BILIARES, TUMORES Y/O TRASTORNOS HIPERPROLIFERATIVOS, Y TRATAMIENTO Y/O PREVENCION DE LA DISMINUCION DE LA TOLERANCIA A LA GLUCOSA Y DIABETES.
GT200100220A 2000-11-02 2001-10-31 Nuevos heteroaromatos. GT200100220A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00123826 2000-11-02

Publications (1)

Publication Number Publication Date
GT200100220A true GT200100220A (es) 2002-07-04

Family

ID=8170270

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100220A GT200100220A (es) 2000-11-02 2001-10-31 Nuevos heteroaromatos.

Country Status (21)

Country Link
US (3) US6951879B2 (es)
EP (1) EP1334094B1 (es)
JP (1) JP4012064B2 (es)
KR (1) KR100545430B1 (es)
CN (1) CN1261429C (es)
AR (1) AR034271A1 (es)
AT (1) ATE286042T1 (es)
AU (2) AU2002214029B2 (es)
BR (1) BR0115075A (es)
CA (1) CA2426009C (es)
DE (1) DE60108164T2 (es)
DK (1) DK1334094T3 (es)
ES (1) ES2233703T3 (es)
GT (1) GT200100220A (es)
MX (1) MXPA03003845A (es)
PA (1) PA8531601A1 (es)
PE (1) PE20020600A1 (es)
PT (1) PT1334094E (es)
UY (1) UY27009A1 (es)
WO (1) WO2002036584A1 (es)
ZA (1) ZA200302742B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60135230D1 (de) 2000-08-16 2008-09-18 Hoffmann La Roche Aminocyclohexan-derivate
US7012077B2 (en) * 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
JP4912314B2 (ja) * 2004-10-26 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 因子Ｘａ化合物
EP1902023A4 (en) * 2005-06-30 2009-08-12 Bayer Cropscience Ag IMPROVED PROCESS FOR PREPARING PHENYLALKYL SUBSTITUTED INSECTICIDE HETEROCYCLES (DISUBSTITUTED PROPENYL)
FR2913019A1 (fr) * 2007-02-23 2008-08-29 Cerep Sa Composes heterocycliques comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
WO2009069011A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
AU2008331167A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine
CA2822207A1 (en) * 2010-12-27 2012-07-05 The Curators Of The University Of Missouri Oxidosqualene cyclase as a protein target for anticancer therapeutics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598839A (en) * 1969-06-30 1971-08-10 Parke Davis & Co Phenylbenzothiophene compounds
GR75101B (es) * 1980-10-23 1984-07-13 Pfizer
GB8417559D0 (en) * 1984-07-10 1984-08-15 Pfizer Ltd Anti-diarrhoeal agents
DE3905364A1 (de) 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
EP0530149A1 (de) * 1991-08-30 1993-03-03 Ciba-Geigy Ag Schädlingsbekämpfungsmittel
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
CA2190699A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Tertiary amines
CA2190708A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні

Also Published As

Publication number Publication date
BR0115075A (pt) 2003-07-29
DE60108164T2 (de) 2006-03-02
DE60108164D1 (de) 2005-02-03
AU2002214029B2 (en) 2004-12-23
ZA200302742B (en) 2004-07-08
US6951879B2 (en) 2005-10-04
CN1261429C (zh) 2006-06-28
PE20020600A1 (es) 2002-07-08
KR100545430B1 (ko) 2006-01-24
US20070099985A1 (en) 2007-05-03
CA2426009A1 (en) 2002-05-10
EP1334094B1 (en) 2004-12-29
ATE286042T1 (de) 2005-01-15
PA8531601A1 (es) 2003-02-14
ES2233703T3 (es) 2005-06-16
AR034271A1 (es) 2004-02-18
US7449483B2 (en) 2008-11-11
US20020086891A1 (en) 2002-07-04
UY27009A1 (es) 2002-06-20
WO2002036584A1 (en) 2002-05-10
US7173043B2 (en) 2007-02-06
MXPA03003845A (es) 2003-07-28
US20050267200A1 (en) 2005-12-01
EP1334094A1 (en) 2003-08-13
DK1334094T3 (da) 2005-05-02
KR20030045166A (ko) 2003-06-09
JP4012064B2 (ja) 2007-11-21
CA2426009C (en) 2008-10-07
AU1402902A (en) 2002-05-15
CN1471522A (zh) 2004-01-28
JP2004513124A (ja) 2004-04-30
PT1334094E (pt) 2005-05-31

Similar Documents

Publication Publication Date Title
PA8557001A1 (es) Nuevos derivados de pirrolidina
PA8562801A1 (es) Nuevos derivados de pirido (2,1-a) isoquinolina
PA8566201A1 (es) Nuevos derivados de piridina y quinolina
AR032065A1 (es) Derivados de glucopiranosiloxipirazol y composicion farmaceutica
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
AR024964A1 (es) Antibacterianos
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
ES2161290T3 (es) Derivados de quinazolina.
DK1156798T3 (da) Felbamat-afledte forbindelser
ES2174465T3 (es) Compuestos triazol y su utilizacion como ligandos de dopamina-d.
IL169184A0 (en) Aromatic compounds as anti-inflammatory, immunomdulatory and anti-proliferatory agents
GT200100220A (es) Nuevos heteroaromatos.
PA8525101A1 (es) Nuevos derivados de aminociclohexanol
GT200100145A (es) Derivados de pirrolidina.
PA8581201A1 (es) Nuevos derivados de tiazol
PA8584501A1 (es) Nuevos derivados de oxazol
NO20031410D0 (no) Antitumorterapi innbefattende distamycinderivater
ATE326451T1 (de) Chinazolin derivate und therapeutische verwendungen davon
UY28535A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
BR0116263A (pt) Derivados de diidroindol e tetraidroquinolina
PA8560001A1 (es) Derivados de ciclohexano sustituidos